Keywords: hgs, completes, enrollment, ph, ii, mapatumumab, trial

HGS completes enrollment in Ph II mapatumumab trial

Article | 01 September 2008

Print This

US drug major Human Genome Sciences has completed the enrollment and initial dosing of patients in a randomized Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in